Biquinoline-phenanthroline ruthenium complex and its preparation method and application
By introducing saturated nitrogen-containing heterocyclic structures into biquinoline-phenanthroline ruthenium complexes, a drug with near-infrared fluorescence characteristics and high singlet oxygen quantum yield is solved, and the instability of the existing photodynamic therapy drug structure is solved. and the problem of low singlet oxygen quantum yield, effective chemical and photodynamic therapy for malignant tumors is achieved.
Patent Information
- Application Number
- CN202310066416.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-01-20
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-01-20
AI Technical Summary
The existing photodynamic therapy drugs have unstable structures and low singlet oxygen quantum yields, making it difficult to significantly inhibit the growth of malignant tumor cells.
Using biquinoline-phenanthroline-phenanthroline-based ruthenium complex, the lipid water partition coefficient is improved by introducing saturated nitrogen-containing heterocyclic structure, with near-infrared fluorescence characteristics and strong tissue penetration, and is prepared together with biquinoline to form A new type of drug with photo-chemotherapy effects.
This drug is not only used for fluorescence imaging of malignant tumors, but also can significantly kill a variety of tumor cells. It has significant chemotherapy and photodynamic therapy effects and synergistically exerts therapeutic effects.
Smart Images

Figure CN116284146B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of drug preparation, and relates to a class of biquinoline-phenanthroline ruthenium complexes and preparation methods and applications thereof, and in particular to a class of biquinoline-phenanthroline ruthenium complexes with photo-chemotherapeutic effects and pharmaceutically acceptable salts thereof, preparation methods thereof and medical uses thereof, in particular, applications thereof in the preparation of drugs for malignant tumors. Background Art
[0002] Photodynamic therapy (PDT) has become an effective treatment for cancer. Photodynamic therapy is a clinical treatment method that uses photosensitizers to produce reactive oxygen species (ROS) under light irradiation of appropriate wavelengths, oxidatively damage tumor cells and inhibit tumor growth. In the past few years, many different photosensitizers have been reported, such as porphyrin, fluoroboron dipyrrole dyes and cyanine dyes, but their photodynamic therapeutic effects are not significant. If photodynamic therapy can be combined with drug chemotherapy, it will further promote the therapeutic effect on malignant tumors.
[0003] Ruthenium complexes are currently the most important photodynamic therapy drugs. They usually contain chelating ligands, such as bipyridine. Ruthenium complexes coordinated with these bidentate ligands have good planarity and high designability. However, there are also some problems such as structural instability and low singlet oxygen. It is necessary to further improve its photodynamic therapy effect by optimizing molecular optical and physical properties through structural modification. Summary of the invention
[0004] In view of this, the purpose of the present invention is to provide a biquinoline-phenanthroline ruthenium complex and its preparation method and application. The biquinoline-phenanthroline ruthenium complex has near-infrared fluorescence characteristics and produces significant chemotherapeutic and photodynamic therapeutic effects on a variety of tumor cells, and can be used in the preparation of drugs for diagnosing or treating malignant tumors.
[0005] To achieve the above object, the present invention provides the following technical solutions:
[0006] A biquinoline-phenanthroline ruthenium complex, the biquinoline-phenanthroline ruthenium complex has a structure shown in the following general formula I:
[0007]
[0008] Among them, R is One of them.
[0009] Furthermore, R is
[0010] The present invention also provides a method for preparing a biquinoline-phenanthroline ruthenium complex, and the synthetic route of the preparation method is shown in the following formula:
[0011]
[0012] Among them, R is One of;
[0013] The preparation method comprises the following steps:
[0014] S1. The methyl group at the 5-position of 5-methyl-1,10-phenanthroline 1 is oxidized to an aldehyde group by selenium dioxide to obtain compound 2, and then compound 2 is directly reduced by sodium borohydride to obtain compound 3, and compound 3 is then substituted with phosphorus tribromide to obtain compound 4, and compound 4 is reacted with various nitrogen heterocycles to obtain compound 5;
[0015] S2.2,2'-Biquinoline 6 undergoes a coordination reaction with hydrated ruthenium trichloride to obtain compound 7. Compound 5, compound 7 and ammonium hexafluorophosphate are added to a mixed solution of water and methanol to undergo a coordination reaction to generate biquinoline-phenanthroline ruthenium complex I.
[0016] The present invention also provides a medicine comprising the above-mentioned biquinoline-phenanthroline ruthenium complex or a pharmaceutically acceptable salt thereof.
[0017] The present invention also provides a use of the above-mentioned biquinoline-phenanthroline ruthenium complex or a pharmaceutically acceptable salt thereof in the preparation of a drug for diagnosing or treating malignant tumors.
[0018] Furthermore, the drug for diagnosing malignant tumors includes a drug for fluorescence imaging of malignant tumors.
[0019] Furthermore, the malignant tumor fluorescence imaging drug is a near-infrared fluorescence imaging drug with mitochondrial targeting.
[0020] Furthermore, the drug for treating malignant tumors is a drug for chemotherapy of malignant tumors and / or photodynamic therapy of malignant tumors.
[0021] Furthermore, the malignant tumor includes breast cancer, colon cancer, lung cancer or cervical cancer.
[0022] Compared with the prior art, the advantages of the present invention are as follows: the present invention uses phenanthroline as the parent nucleus, and synthesizes a novel hydrophilic phenanthroline ligand through modification with a hydrophilic nitrogen-containing heterocycle, and then prepares and develops a biquinoline-phenanthroline ruthenium complex with photo-chemotherapeutic effect together with biquinoline. The biquinoline-phenanthroline ruthenium complex has improved lipid-water partition coefficient due to the introduction of a saturated nitrogen-containing heterocyclic structure, has near-infrared fluorescence characteristics, strong tissue penetration, and has the advantages of large Stokes shift, low tissue background fluorescence interference, good photostability and high singlet oxygen quantum yield. It can not only be used for fluorescence imaging of tumor cells, but also has significant chemotherapeutic and photodynamic therapeutic effects on a variety of tumor cells, exerts a synergistic therapeutic effect, can effectively kill tumor cells, and can be used in the preparation of drugs for diagnosing or treating malignant tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 The ultraviolet absorption spectrum of the compound provided by the present invention;
[0024] Figure 2 The fluorescence emission spectrum of the compound provided by the present invention;
[0025] Figure 3 This is a graph showing the results of co-localization fluorescence imaging of A549 cells by compound I2 provided by the present invention. DETAILED DESCRIPTION
[0026] In order to further illustrate the present invention, a series of examples are given below. These examples are purely illustrative and are only used to specifically describe the present invention, and should not be understood as limiting the present invention.
[0027] Example 1: Preparation of 5-((4-piperidone)-N-methylene)-1,10-phenanthroline-bis(2,2'-biquinoline)ruthenium di(hexafluorophosphate) salt (I1)
[0028] Step 1: Preparation of 5-formaldehyde-1,10-phenanthroline (Compound 2)
[0029] Compound 1 (5-methyl-1,10-phenanthroline, 10mmol, 1.940g) and SeO2 (30mmol, 1.111g) were dissolved in 1,3-dichlorobenzene (10mL), protected by nitrogen, and refluxed at 165℃ for 3h. Thin layer chromatography was used to monitor whether the reaction was complete. After the reaction was completed, the reaction solution was cooled to room temperature, 1,3-dichlorobenzene was first sucked out with a plastic pipette, and the remaining black solid was washed with MeOH (10mL×3) and the solid was filtered out. The filtrate was mixed with the previous 1,3-dichlorobenzene, and the organic layer was dried with anhydrous Na2SO4. MeOH was removed by decompression, and the crude product was purified by column chromatography (ammonia MeOH: DCM=1:15) to obtain compound 2 (1.873g) as a white solid with a yield of 90%. 1 H NMR (400MHz, DMSO-d6) δ10.32(s,1H,CH),9.57(dd,J=8.5,1.8Hz,1H,ArH),9.18(dd,J=4.4,1 .8Hz,1H,ArH),9.10(dd,J=4.3,1.8Hz,1H,ArH),8.62–8.53(m,2H,2ArH),7.77(m,2H,2ArH). 13 C NMR (101MHz, DMSO) δ193.5,153.2,150.7,147.6,145.8,140.4,138.4,133.8,130.1,127.2,125.5,124.5.
[0030] Step 2: Preparation of 5-hydroxymethyl-1,10-phenanthroline (Compound 3)
[0031] Compound 2 (8 mmol, 1.664 g) was dissolved in CH3CH2OH (20 mL), stirred for 5 min, and then NaBH4 (16 mmol, 0.605 g) was added and reacted for 1 h. The reaction was monitored by thin layer chromatography. After the reaction was completed, 1 to 2 drops of water were added to quench the reaction, and then the solvent was removed by vortexing under reduced pressure. Saturated brine (30 mL) was added and extracted with DCM (20 mL×3). The organic layer was dried over anhydrous Na2SO4, and the organic solvent was removed by vortexing under reduced pressure to obtain intermediate 3 (1.215 g) as a light yellow solid with a yield of 73%. 1 H NMR (400MHz, DMSO-d6) δ9.01 (m, 2H, 2ArH), 8.52 (dd, J=8.4, 1.7Hz, 1H, ArH), 8.39 (dd, J=8.1, 1.8Hz,1H,ArH),7.90(s,1H,ArH),7.69(m,2H,2ArH),5.58(m,1H,OH),5.04–4.94(m,2H,CH2). 13C NMR (101MHz, DMSO) δ193.5,153.2,150.7,147.60,145.8,140.4,138.4,133.8,130.1,127.2,125.5,124.5.
[0032] Step 3: 5-Bromomethyl-1,10-phenanthroline (Compound 4)
[0033] Compound 3 (6mmol, 1.260g) was dissolved in DCM (20mL), stirred in an ice bath for 5min, and then PBr3 (6mmol, 1.624g) was slowly added dropwise. After stirring for 10min, the reaction liquid temperature was restored to room temperature and reacted for 12h. The reaction was monitored by thin layer chromatography to see if it was complete. After the reaction was complete, the pH was adjusted to 7 with 2mol / L NaHCO3, and then extracted with DCM (20mL×3). The organic layer was dried with anhydrous Na2SO4, and the organic solvent was removed under reduced pressure to obtain compound 4 (1.306g) as a light yellow solid with a yield of 80%. 1 HNMR(400MHz,CD3OD)δ9.00(m,2H,2ArH),8.64(dd,J=8.4,1.7Hz,1H,ArH),8.34–8.28(m,1H,ArH),7 .95(s,1H,ArH),7.74(dd,J=8.0,4.1Hz,1H,ArH),7.65(dd,J=8.1,4.4Hz,1H,ArH),5.02(s,2H,CH2). 13 C NMR (101MHz, CD3OD) δ149.9,149.5,145.2,144.9,137.0,133.6,133.1,128.2,127.5,126.9,123.8,123.3,29.5.
[0034] Step 4: 5-(Piperidinyl-N-methylene)-1,10-phenanthroline (Compound 5a)
[0035] Compound 4 (4mmol, 1.088g), piperidone (4mmol, 0.396g) and K2CO3 (4mmol, 0.553g) were dissolved in MeCN (20mL), stirred for 5min, and then 1-2 drops of DMF were added dropwise. The mixture was refluxed at 85°C for 12h under nitrogen protection. The reaction was monitored by thin layer chromatography. After the reaction was completed, saturated brine (20mL) was added, and then extracted with DCM (20mL×3). The organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by column chromatography (ammonia MeOH:DCM=1:20) to obtain the target compound 5a (0.815g) as a light yellow solid with a yield of 70%. 1H NMR (400MHz, CDCl3) δ9.07(m,2H,2ArH),8.71(dd,J=8.4,1.7Hz,1H,ArH),8.10(dd,J=8.1,1.7Hz,1H,ArH),7.5 9(s,1H,ArH),7.52(m,2H,2ArH),3.79(s,2H,CH2),2.41–2.35(m,2H,CH2),1.41(m,6H,3CH2),1.17(s,2H,CH2). 13 C NMR (101MHz, CDCl3) δ149.9,149.8,146.4,146.1,135.6,133.7,133.6,128.6,127.9,126.5,123.0,122.5,61.8,54.7,26.0,24.3.HRMS (ESI) m / z calcd for C18H19N3[M+H]+,278.1657; found,278.1670.
[0036] Step 5: Bisquinoline ruthenium dichloride (Compound 7)
[0037] 2,2'-Biquinoline (6mmol, 1.536g), LiCl (3mmol, 0.127g) and hydrated ruthenium trichloride (3mmol, 0.622g) were dissolved in anhydrous DMF (25ml) and heated to reflux at 165℃ for 8h. The reaction was monitored by thin layer chromatography to see if it was complete. After the reaction was completed, it was cooled to room temperature, 150ml of acetone was added to the reaction solution, and then placed at 0℃ overnight. The solution was filtered out using filter paper, leaving the solid, which was washed with water (5mL×3) and chloroform (10mL×3). The solid was vacuum dried and then purified by column chromatography (ammonia MeOH: DCM=1:20) to obtain compound 7 (1.108g) as a green solid with a yield of 54%. 1 H NMR (400MHz, DMSO-d6) δ8.72(dd,J=8.2,1.2Hz,8H,8ArH),8.26–8.19(m,8H,8ArH),8.14(d,J=8.9Hz,4H,4ArH),7.69(d,J=5.4Hz,4H,4ArH).
[0038] Step 6: Preparation of 5-((4-piperidinone)-N-methylene)-1,10-phenanthroline-bis(2,2'-biquinolinol)ruthenium di(hexafluorophosphate) salt (I1)
[0039] Compound 7 (0.5mmol, 0.342g) and compound 5a (0.5mmol, 0.145g) were dissolved in MeOH / H2O (6mL, v / v=1 / 2) and heated to reflux at 95°C for 4.5h. The reaction was monitored by thin layer chromatography to see if it was complete. After the reaction was completed, the mixture was cooled to room temperature, and ammonium hexafluorophosphate (2mmol, 0.326g) was added to the reaction solution and stirred for 10min. After stirring, the solution was filtered out using filter paper to leave the solid. The solid was washed with triple distilled water (5mL×3) and chloroform (10mL×3), and then the solid was vacuum dried. The crude product was purified by column chromatography (ammonia MeOH:DCM=1:25) to obtain the target compound I1 as a purple-black solid with a yield of 62%. 1 HNMR (400MHz, DMSO-d6) δ9.42(m,2H,2ArH),9.27–9.12(m,4H,4ArH),8.82(d,J=8.5Hz,1H,ArH),8.61(dd,J=18. 6,8.8Hz,2H,2ArH),8.48–8.40(m,3H,3ArH),8.29(dd,J=8.4,1.4Hz,2H,2ArH),7.87(m,2H,2ArH),7.81–7.68(m, 3H,3ArH),7.58(m,2H,2ArH),7.39(dd,J=9.0,4.3Hz,2H,2ArH),7.28(m,2H,2ArH),7.18(m,3H,3ArH),7.05(m,1 H,ArH),6.91–6.81(m,2H,2ArH),4.07–3.92(m,2H,CH2),2.48(m,2H,CH2),2.40(dm,2H,CH2),2.24(m,4H,2CH2). 13 C NMR(101MHz,DMSO)δ208.3,161.4,160.9,153.2,153.1,151.7,150.0,149. 9,146.8,146.2,140.9,139.1,138.0,136.3,135.4,133.1,130.9,130.8,1 30.4,129.8,129.4,129.0,128.7,128.2,127.9,127.9,127.6,126.6,126.0,125.3,125.1,125.0,123.3,122.1,122.0,60.2,57.4,52.2,21.2,14.5.
[0040] Example 2: Preparation of 5-((N-benzylpiperazine)-N-methylene)-1,10-phenanthroline-bis(2,2'-biquinoline)ruthenium di(hexafluorophosphate) salt (I2)
[0041] (1) Preparation of 5-((N-benzylpiperazine)-N-methylene)-1,10-phenanthroline (Compound 5b)
[0042] Referring to the method described for compound 5a, N-benzylpiperazine was used instead of piperidone to react with compound 4 to obtain compound 5b (1.059 g, 72%) as a light yellow solid. 1 H NMR (400MHz, CDCl3) δ9.17(m,2H,2ArH),8.77(dd,J=8.4,1.8Hz,1H,ArH),8.20(dd,J=8.1,1.8Hz,1H,ArH),7.70(s,1H, ArH),7.63(m,2H,2ArH),7.35–7.29(m,5H,5ArH),3.96(s,2H,CH2),3.53(s,2H,CH2),2.65(dd,J=6.2,4.7Hz,8H,4CH2). 13 C NMR (101MHz, CDCl3) δ150.1,150.0,146.4,146.2,135.7,133.7,133.0,129.3,129.0,1 28.4,128.2,127.9,127.2,126.9,123.1,122.6,62.9,61.1,53.0,53.0.HRMS(ESI)m / z calcd for C 24 H 24 N4[M+H] + ,369.2079;found,369.2083.
[0043] (2) Preparation of 5-((N-benzylpiperazine)-N-methylene)-1,10-phenanthroline-bis(2,2'-biquinoline)ruthenium di(hexafluorophosphate) salt (I2)
[0044] Referring to the method described for compound I1, compound 5b was used instead of compound 5a to react with compound 7 to obtain compound I2 (0.413 g, 65%) as a purple-black solid. 1H NMR (400MHz, DMSO-d6) δ9.41(dd,J=12.4,8.8Hz,2H,2ArH),9.21(m,3H,3ArH),9.14(d,J=8.6Hz,1H,ArH),8.71(d,J=8.5Hz,1 H,ArH),8.61(d,J=8.6Hz,1H,ArH),8.56(d,J=8.8Hz,1H,ArH),8.42(m,3H,3ArH),8.29(d,J=8.0Hz,2H,2ArH),7.85(m,2H,2Ar H),7.75(dd,J=13.4,8.1Hz,2H,2ArH),7.68(s,1H,ArH),7.58(d,J=7.4Hz,1H,ArH),7.38-7.15(m,13H,13ArH),7.00(d,J=8.8 Hz,1H,ArH),6.87(m,1H,ArH),6.80(m,1H,ArH),3.97-3.70(m,2H,CH2),3.56(d,J=13.5Hz,2H,CH2),2.43-1.99(m,8H,4CH2). 13 C NMR (101MHz, DMSO) δ161.46,160.98,153.07,151.73,150.08,146.75,146.21,140.96,139. 18,137.97,136.39,133.14,130.42,129.80,129.45,125.18,123.31,122.19,55.38,52.79.
[0045] Example 3: Measurement of UV absorption and fluorescence emission spectra of the compounds of the present invention
[0046] (1) Ultraviolet absorption spectrum of the compound of the present invention
[0047] Using methanol as solvent, the compounds of the present invention were prepared into 10 μM sample solutions, and recorded using a UV-visible spectrophotometer. The temperature when recording the UV absorption spectrum was room temperature, the wavelength range of the scanning absorption spectrum was 200-800 nm, and the scanning speed was 1.0 nm / s. The UV absorption spectra of the compounds in methanol solutions were characterized as follows: Figure 1 As shown. Figure 1 It can be found that the absorption spectrum of the biquinoline-phenanthroline ruthenium complex of the present invention has a very strong absorption peak in the range of 500-600nm, which may be caused by the dπ-π* electronic transition (MLCT) between the metal Ru and the ligand biq.
[0048] (2) Fluorescence emission spectra of the compounds of the present invention
[0049] The compound of the present invention was prepared into a 10 μM sample solution using methanol as solvent, and the fluorescence emission spectrum of the ruthenium complex was recorded using a fluorescence spectrophotometer with an excitation wavelength of 452 nm. The temperature when recording the emission spectrum was room temperature. The fluorescence emission spectra of the ruthenium complex in methanol solution were characterized as follows: Figure 2 The wavelength range of the scanning emission spectrum is 470-900nm, and the scanning speed is 1.0nm / s. Figure 2 It can be found that the maximum wavelength of the fluorescence emission spectrum of the biquinoline-phenanthroline ruthenium complex of the present invention appears in the range of 700-780nm, and the wavelength of the fluorescence reaches the near-infrared light range.
[0050] Example 6 Determination of Singlet Oxygen Quantum Yield of Compounds of the Invention
[0051] We selected DPBF as a singlet oxygen scavenger and methanol as the solvent. In methanol, the absorbance of DPBF at 412 nm was adjusted to about 1.0; then, in order to reduce the singlet oxygen quenching of the control and the compound to be tested, I1, I2 and the control [Ru(bpy)3] 2+ The absorbance values at 520 nm were adjusted to below 0.1. Then, the transparent side of the quartz cell was exposed to a laser (40 mW) with a wavelength of 520 nm for a total of 5 minutes. The absorption spectrum was recorded at different time periods during the 5 minutes. The scanning wavelength range was 300-600 nm, and the scanning speed was 1.0 nm / s.
[0052] With the known singlet oxygen quantum yield of [Ru(bpy)3] 2+ As a standard, the singlet oxygen quantum yield was calculated by the following formula:
[0053] Φ T =Φ X (S T F X / SxF T )
[0054] Φ: singlet oxygen quantum yield; S: the slope of the straight line with irradiation time as x-axis and the UV absorbance of DPBF at 412nm after the corresponding irradiation time as y-axis; F: absorption correction factor of unknown sample and reference standard, F = 1-10 -OD OD represents the ultraviolet absorption value of the compound under the irradiation wavelength; X and T represent the reference standard and the unknown sample, respectively. The results are shown in Table 1. We found that the compounds of the present invention all have a high singlet oxygen quantum yield, which helps to exert an efficient photodynamic therapy effect.
[0055] Table 1 Singlet oxygen quantum yield of the compounds of the present invention
[0056]
[0057] Example 7 The tumor cell proliferation inhibition rate of the compound of the present invention was determined by MTT method
[0058] MTT was routinely used to evaluate the cytotoxicity of the compounds of the present invention to human colon cancer cells HT29, human breast cancer cells MCF-7, human lung adenocarcinoma cells A549, and human cervical cancer cells Hela under dark conditions and after irradiation with light of a specific wavelength. The MTT method has been widely used in large-scale anti-tumor drug screening, cytotoxicity tests, etc. 2+ As a positive control drug.
[0059] The experimental method is as follows: Take a bottle of cells in good exponential growth phase, add 0.25% trypsin to digest, so that the attached cells fall off, and make a mixture containing 2×10 4 ~4×10 4 The cell suspension was inoculated on a 96-well plate, 180 μL per well, and cultured in a constant temperature CO2 incubator for 24 hours. The medium was changed and the test compounds I1 and I2 and the positive control drug [Ru(bpy)3] were added. 2+ (The compounds were dissolved in DMSO and then diluted with PBS. The concentrations of the tested compounds were 12.5×10 -6 mol / L), 20μL was added to each well, the Dark group was directly cultured for 24 hours, the Light group was incubated for 2h, illuminated with 520nm excitation light for 10min, and then continued to culture for 22 hours. MTT was added to a 96-well plate, 20μL per well, and reacted in an incubator for 4h. The supernatant was aspirated, DMSO was added, 150μL per well, and shaken on a plate shaker for 5 minutes. The absorbance of each well was measured at a wavelength of 570nm using an enzyme-linked immunosorbent assay, and the cell inhibition rate was calculated. The experimental results are shown in Table 2.
[0060] Cell inhibition rate = (OD value of negative control group - OD value of test substance group) / OD value of negative control group × 100%.
[0061] The compounds of the present invention were tested for their anti-proliferative activity on tumor cells. The pharmacological experimental results showed (see Table 2) that under dark conditions, the compounds I1 and I2 of the present invention had different degrees of anti-tumor activity on tumor cells at a concentration of 12.5 μM, while the wavelength of 520 nm (200 mW / cm -2 After 10 min of LED light irradiation, the survival rate of tumor cells was significantly reduced, showing a more potent anti-tumor cell activity, which was significantly stronger than the positive control drug [Ru(bpy)3] 2+This indicates that the compound of the present invention not only has a photodynamic therapy effect, but also has a significant chemotherapeutic effect, a photo-chemotherapeutic effect, and synergistically exerts a significant anti-cancer effect.
[0062] Table 2 Survival rate of some compounds of the present invention on human cancer cells (12.5 μM)
[0063]
[0064] ND: Not tested.
[0065] Example 8: Cell fluorescence imaging and organelle co-localization experiments using confocal microscopy
[0066] A confocal microscope was used to conduct cell fluorescence imaging and mitochondrial localization experiments. Lung cancer A549 cells were cultured in a laser confocal dish with DEME culture medium for 12 to 24 hours, and 5 to 20 μM of the test compound of the present invention was added. The cells were placed in a cell culture incubator at 37°C and 5% CO2 for half an hour. Then, the cells were washed three times with a phosphate buffer solution at pH = 7.4, and then 1 μM of the mitochondrial dye MitoTracker red solution was added and incubated for another half an hour. The cells were then washed three times with a phosphate buffer solution at pH = 7.4. The incubated cells were placed on the stage of a confocal microscope for confocal fluorescence imaging. The excitation wavelength of the test compound was set to: λex = 500-580nm, and the emission wavelength λem = 720-780nm. Results Figure 3 shown.
[0067] according to Figure 3 It can be seen that the experimental results show that the compound I2 described in the present invention can clearly produce fluorescent images of tumor cells, and overlaps well with the fluorescent imaging of mitochondrial probes, indicating that the compound of the present invention can target and locate in mitochondria in tumor cells.
Claims
1. A biquinoline-phenanthroline ruthenium complex, characterized in that: The biquinoline-phenanthroline ruthenium complex has a structure shown in the following general formula I: Among them, R is 2. A method for preparing the biquinoline-phenanthroline ruthenium complex according to claim 1, characterized in that: The synthetic route of the preparation method is shown below: Among them, R is The preparation method comprises the following steps: S1. The methyl group at the 5-position of 5-methyl-1,10-phenanthroline 1 is oxidized to an aldehyde group by selenium dioxide to obtain compound 2, and then compound 2 is directly reduced by sodium borohydride to obtain compound 3, and compound 3 is then substituted with phosphorus tribromide to obtain compound 4, and compound 4 is reacted with various nitrogen heterocycles to obtain compound 5; S2.2,2'-Biquinoline 6 undergoes a coordination reaction with hydrated ruthenium trichloride to obtain compound 7. Compound 5, compound 7 and ammonium hexafluorophosphate are added to a mixed solution of water and methanol to undergo a coordination reaction to generate biquinoline-phenanthroline ruthenium complex I.
3. A drug comprising the biquinoline-phenanthroline ruthenium complex or a pharmaceutically acceptable salt thereof as claimed in claim 1.
4. Use of the biquinoline-phenanthroline ruthenium complex or a pharmaceutically acceptable salt thereof according to claim 1 in the preparation of a drug for diagnosing or treating malignant tumors, wherein the malignant tumor comprises one of breast cancer, colon cancer, lung cancer and cervical cancer.
5. The use according to claim 4, characterized in that: The drug for diagnosing malignant tumors is a drug for fluorescence imaging of malignant tumors.
6. The use according to claim 5, characterized in that: The malignant tumor fluorescence imaging drug is a near-infrared fluorescence imaging drug with mitochondrial targeting.
7. The use according to claim 4, characterized in that: The drug for treating malignant tumors is a drug for chemotherapy of malignant tumors and / or photodynamic therapy of malignant tumors.
